• PharmaMar SA, of Madrid, a subsidiary of Zeltia SA, said it completed enrollment in its Phase IIb study testing PM01183 vs. topotecan in resistant/refractory ovarian cancer. The open-label study is designed to confirm PM01183's activity in that indication.